Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Daklinza
TMC435 (also known as daclatasvir) is a direct-acting antiviral agent (DAA) specifically targeting the NS5A protein of the hepatitis C virus (HCV). It is used in combination with other antiviral drugs for the treatment of chronic HCV infection. TMC435 is a small molecule inhibitor that disrupts the HCV lifecycle by interfering with viral replication and assembly.
For the treatment of chronic hepatitis C virus (HCV) infection in combination with other antiviral agents.
Outcome:
Reduced TMC435 concentration
Mechanism:
Induction of CYP3A4
Outcome:
Increased TMC435 concentration
Mechanism:
Inhibition of CYP3A4
Outcome:
Slightly reduced TMC435 absorption
Mechanism:
Changes in gastric pH
Most likely new formulation: Long-acting injectable version (Year 2026, 60% confidence)
Based on historical approval rates for HCV drugs with similar mechanisms of action, there is a high (80%) likelihood of continued regulatory support for TMC435 in combination therapies.
Antiviral, Direct-acting Antiviral Agent (DAA)
Cyclopropyl carboxamide